primary antibodies against c fos  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc primary antibodies against c fos
    Primary Antibodies Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against c fos/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against c fos - by Bioz Stars, 2023-11
    86/100 stars

    Images

    primary antibodies against c fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc primary antibodies against c fos
    Primary Antibodies Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against c fos/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against c fos - by Bioz Stars, 2023-11
    86/100 stars

    Images

    primary antibodies against c fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Cell Signaling Technology Inc primary antibodies against c fos
    Primary Antibodies Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against c fos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against c fos - by Bioz Stars, 2023-11
    97/100 stars

    Images

    rabbit monoclonal primary antibody against cfos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Cell Signaling Technology Inc rabbit monoclonal primary antibody against cfos
    Rabbit Monoclonal Primary Antibody Against Cfos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal primary antibody against cfos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit monoclonal primary antibody against cfos - by Bioz Stars, 2023-11
    97/100 stars

    Images

    primary antibodies against c fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Cell Signaling Technology Inc primary antibodies against c fos
    Primary Antibodies Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against c fos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against c fos - by Bioz Stars, 2023-11
    97/100 stars

    Images

    primary antibody against cfos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Cell Signaling Technology Inc primary antibody against cfos
    Primary Antibody Against Cfos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against cfos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibody against cfos - by Bioz Stars, 2023-11
    97/100 stars

    Images

    primary antibodies against fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Cell Signaling Technology Inc primary antibodies against fos
    CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control <t>construct</t> <t>(AAV-GFP),</t> CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of <t>Fos</t> expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S2 . Complete statistical summaries are provided in . " width="250" height="auto" />
    Primary Antibodies Against Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against fos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against fos - by Bioz Stars, 2023-11
    97/100 stars

    Images

    1) Product Images from "Gene-environment interactions mediate stress susceptibility and resilience through the CaMKIIβ/TARPγ-8/AMPAR pathway"

    Article Title: Gene-environment interactions mediate stress susceptibility and resilience through the CaMKIIβ/TARPγ-8/AMPAR pathway

    Journal: iScience

    doi: 10.1016/j.isci.2021.102504

    CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control construct (AAV-GFP), CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of Fos expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S2 . Complete statistical summaries are provided in . " title="... group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of Fos expression in the vCA1 of BALB mice. n ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control construct (AAV-GFP), CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of Fos expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also Figure S2 . Complete statistical summaries are provided in .

    Techniques Used: Activation Assay, Construct, Expressing, Over Expression, Injection, Two Tailed Test

    CaMKIIβ inhibition in the vCA1 increases stress susceptibility (A) AAV vectors used for the control construct (AAV-shControl) and CaMKIIβ knockdown (AAV-shCaMKIIβ). ITR, inverted terminal repeats; P CMV , cytomegalovirus promoter; P Camk2a , Camk2a promoter; U6, U6 promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental paradigm for behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (D) Specific knockdown of CaMKIIβ but not CaMKIIα by the AAV-shCaMKIIβ. (E–G) CaMKIIβ knockdown in the vCA1 of B6 mice leads to significantly decreased social interaction time in the SIT (E), decreased sucrose preference in SPT (F), and increased immobility time in FST (G) following CUMS exposure. n = 12–15 mice per group. (H) AAV vectors engineered to overexpress a constitutively active form of CaMKIIβ (CaMKIIβ-CA) with resistance against shCaMKIIβ (AAV-CaMKIIβ-CA Res ) or a control construct (AAV-mCherry). (I) Experimental paradigm for behavioral testing. (J) AAV microinjection into the vCA1. Region-specific expression of GFP and mCherry in the vCA1 is shown. Scale bar, 100 μm. (K and L) Overexpression of CaMKIIβ-CA Res together with shCaMKIIβ increases time in the interaction zone in the SIT (K) and tends to increase sucrose preference in the SPT (L) in B6 mice, when compared to the mice overexpressing mCherry together with shCaMKIIβ. n = 14–15 mice per group. (M) Experimental paradigm for behavioral testing. smSDS, subchronic and mild social defeat stress. (N) Decreased time in the interaction zone in B6 mice given AAV-shCaMKIIβ following smSDS exposure is prevented by overexpression of CaMKIIβ-CA Res . n = 15–16 mice per group. (O) AAV vectors engineered to overexpress a dominant-negative form of CaMKIIβ (AAV-CaMKIIβ-DN) or a control construct (AAV-GFP). (P) Experimental paradigm for behavioral testing. (Q) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (R–S) Overexpression of CaMKIIβ-DN decreases time in the interaction zone in the SIT (R) and sucrose preference in the SPT (S) in B6 mice following smSDS. n = 13–15 mice per group. (T) Overexpression of CaMKIIβ-DN decreases Fos levels in the vCA1 of B6 mice following smSDS exposure. n = 6 for all groups. Two-way ANOVA followed by a Tukey's post hoc test (in E-G, N, R, and S), one-way ANOVA followed by a Tukey's post hoc test (in N), and two-tailed Student's t-test (in K, L, and T) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S3 . Complete statistical summaries are provided in . " title="... mice per group. (T) Overexpression of CaMKIIβ-DN decreases Fos levels in the vCA1 of B6 mice following ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: CaMKIIβ inhibition in the vCA1 increases stress susceptibility (A) AAV vectors used for the control construct (AAV-shControl) and CaMKIIβ knockdown (AAV-shCaMKIIβ). ITR, inverted terminal repeats; P CMV , cytomegalovirus promoter; P Camk2a , Camk2a promoter; U6, U6 promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental paradigm for behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (D) Specific knockdown of CaMKIIβ but not CaMKIIα by the AAV-shCaMKIIβ. (E–G) CaMKIIβ knockdown in the vCA1 of B6 mice leads to significantly decreased social interaction time in the SIT (E), decreased sucrose preference in SPT (F), and increased immobility time in FST (G) following CUMS exposure. n = 12–15 mice per group. (H) AAV vectors engineered to overexpress a constitutively active form of CaMKIIβ (CaMKIIβ-CA) with resistance against shCaMKIIβ (AAV-CaMKIIβ-CA Res ) or a control construct (AAV-mCherry). (I) Experimental paradigm for behavioral testing. (J) AAV microinjection into the vCA1. Region-specific expression of GFP and mCherry in the vCA1 is shown. Scale bar, 100 μm. (K and L) Overexpression of CaMKIIβ-CA Res together with shCaMKIIβ increases time in the interaction zone in the SIT (K) and tends to increase sucrose preference in the SPT (L) in B6 mice, when compared to the mice overexpressing mCherry together with shCaMKIIβ. n = 14–15 mice per group. (M) Experimental paradigm for behavioral testing. smSDS, subchronic and mild social defeat stress. (N) Decreased time in the interaction zone in B6 mice given AAV-shCaMKIIβ following smSDS exposure is prevented by overexpression of CaMKIIβ-CA Res . n = 15–16 mice per group. (O) AAV vectors engineered to overexpress a dominant-negative form of CaMKIIβ (AAV-CaMKIIβ-DN) or a control construct (AAV-GFP). (P) Experimental paradigm for behavioral testing. (Q) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (R–S) Overexpression of CaMKIIβ-DN decreases time in the interaction zone in the SIT (R) and sucrose preference in the SPT (S) in B6 mice following smSDS. n = 13–15 mice per group. (T) Overexpression of CaMKIIβ-DN decreases Fos levels in the vCA1 of B6 mice following smSDS exposure. n = 6 for all groups. Two-way ANOVA followed by a Tukey's post hoc test (in E-G, N, R, and S), one-way ANOVA followed by a Tukey's post hoc test (in N), and two-tailed Student's t-test (in K, L, and T) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also Figure S3 . Complete statistical summaries are provided in .

    Techniques Used: Inhibition, Construct, Expressing, Over Expression, Dominant Negative Mutation, Two Tailed Test


    Figure Legend Snippet:

    Techniques Used: Produced, Plasmid Preparation, Recombinant, SYBR Green Assay, Multiplex Assay, Mutagenesis, Staining, Western Blot, Real-time Polymerase Chain Reaction, Software

    primary antibodies against p c fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc primary antibodies against p c fos
    Primary Antibodies Against P C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against p c fos/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against p c fos - by Bioz Stars, 2023-11
    96/100 stars

    Images

    primary antibodies against c fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Cell Signaling Technology Inc primary antibodies against c fos
    D.P inhibited RANKL‐induced osteoclast‐specific gene expression. Real‐time PCR was utilized to determine the expression levels of osteoclast‐specific genes, Acp5 <t>,</t> <t>c‐fos</t> , Ctsk and Mmp9 . Expression levels were normalized to the mean of Hprt1 and Hmbs . Data were presented as fold changes relative to RANKL control group. n = 3; * P < .05, ** P < .01, *** P < .001
    Primary Antibodies Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against c fos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against c fos - by Bioz Stars, 2023-11
    97/100 stars

    Images

    1) Product Images from "Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity"

    Article Title: Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity

    Journal: Journal of Cellular and Molecular Medicine

    doi: 10.1111/jcmm.15003

    D.P inhibited RANKL‐induced osteoclast‐specific gene expression. Real‐time PCR was utilized to determine the expression levels of osteoclast‐specific genes, Acp5 , c‐fos , Ctsk and Mmp9 . Expression levels were normalized to the mean of Hprt1 and Hmbs . Data were presented as fold changes relative to RANKL control group. n = 3; * P < .05, ** P < .01, *** P < .001
    Figure Legend Snippet: D.P inhibited RANKL‐induced osteoclast‐specific gene expression. Real‐time PCR was utilized to determine the expression levels of osteoclast‐specific genes, Acp5 , c‐fos , Ctsk and Mmp9 . Expression levels were normalized to the mean of Hprt1 and Hmbs . Data were presented as fold changes relative to RANKL control group. n = 3; * P < .05, ** P < .01, *** P < .001

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction

    D.P supressed osteoclast marker protein expression. (A) Representative images of Western blot on the effects of D.P on osteoclast‐specific proteins during osteoclastogenesis, c‐Fos, Integrin β3, MMP9 and CTSK. β‐actin was used as a loading control. (B) Quantitative analysis of the band intensities relative to β‐actin intensity. n = 3; * P < .05, *** P < .001
    Figure Legend Snippet: D.P supressed osteoclast marker protein expression. (A) Representative images of Western blot on the effects of D.P on osteoclast‐specific proteins during osteoclastogenesis, c‐Fos, Integrin β3, MMP9 and CTSK. β‐actin was used as a loading control. (B) Quantitative analysis of the band intensities relative to β‐actin intensity. n = 3; * P < .05, *** P < .001

    Techniques Used: Marker, Expressing, Western Blot

    primary rabbit antibody against c fos  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc primary rabbit antibody against c fos
    Primary Rabbit Antibody Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary rabbit antibody against c fos/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary rabbit antibody against c fos - by Bioz Stars, 2023-11
    96/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc primary antibodies against c fos
    Primary Antibodies Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against c fos/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against c fos - by Bioz Stars, 2023-11
    86/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc rabbit monoclonal primary antibody against cfos
    Rabbit Monoclonal Primary Antibody Against Cfos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal primary antibody against cfos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit monoclonal primary antibody against cfos - by Bioz Stars, 2023-11
    97/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc primary antibody against cfos
    Primary Antibody Against Cfos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against cfos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibody against cfos - by Bioz Stars, 2023-11
    97/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc primary antibodies against fos
    CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control <t>construct</t> <t>(AAV-GFP),</t> CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of <t>Fos</t> expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S2 . Complete statistical summaries are provided in . " width="250" height="auto" />
    Primary Antibodies Against Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against fos/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against fos - by Bioz Stars, 2023-11
    97/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc primary antibodies against p c fos
    CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control <t>construct</t> <t>(AAV-GFP),</t> CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of <t>Fos</t> expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S2 . Complete statistical summaries are provided in . " width="250" height="auto" />
    Primary Antibodies Against P C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against p c fos/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary antibodies against p c fos - by Bioz Stars, 2023-11
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc primary rabbit antibody against c fos
    CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control <t>construct</t> <t>(AAV-GFP),</t> CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of <t>Fos</t> expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S2 . Complete statistical summaries are provided in . " width="250" height="auto" />
    Primary Rabbit Antibody Against C Fos, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary rabbit antibody against c fos/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    primary rabbit antibody against c fos - by Bioz Stars, 2023-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control construct (AAV-GFP), CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of Fos expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S2 . Complete statistical summaries are provided in . " width="100%" height="100%">

    Journal: iScience

    Article Title: Gene-environment interactions mediate stress susceptibility and resilience through the CaMKIIβ/TARPγ-8/AMPAR pathway

    doi: 10.1016/j.isci.2021.102504

    Figure Lengend Snippet: CaMKIIβ activation in the vCA1 drives stress resilience and has antidepressant-like effect (A) AAV vectors engineered to overexpress a control construct (AAV-GFP), CaMKIIβ (AAV-CaMKIIβ), or a constitutively active form of CaMKIIβ (AAV-CaMKIIβ-CA). ITR, inverted terminal repeats; P Camk2a , Camk2a promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental timeline for chronic stress and behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) Schematic representation showing the microinjection of AAV into the vCA1 region of mice. Region-specific expression of GFP in vCA1 but not dCA1 is shown. Scale bar, 500 μm. (D–F) BALB mice overexpressing CaMKIIβ or CaMKIIβ-CA show significantly increased social interaction time in the SIT (D), increased sucrose preference in the SPT (E), and decreased immobility time in the FST (F) under stress. n = 12–13 mice per group. (G) CaMKIIβ-CA overexpression prevents CUMS-induced reduction of Fos expression in the vCA1 of BALB mice. n = 6 mice per group. (H) AAV-mediated spatiotemporal gene expression strategy using a cocktail of AAV- Camk2a -tTA and AAV-TRE-CaMKIIβ-CA or AAV-TRE-GFP. (I) Experimental timeline for CaMKIIβ-CA overexpression after the termination of CUMS episodes. BALB mice were treated with doxycycline (dox) after AAV injection and exposed 21 days later to CUMS for 6 weeks; they were then taken off dox, and 4 days later behavioral tests were performed. (J) AAV microinjection into the vCA1 region. Region-specific and dox-regulated expression of GFP in the vCA1 is shown. Scale bar, 200 μm. (K–M) CaMKIIβ activation after CUMS leads to a significant increase in social interaction time in the SIT (K), a tendency for increased sucrose preference in the SPT (L), and reduced immobility time in the FST (M). n = 15–16 mice per group. One-way ANOVA followed by a Tukey's post hoc test (in D-G) and two-tailed Student's t-test (in K-M) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also Figure S2 . Complete statistical summaries are provided in .

    Article Snippet: Free-floating sections were incubated with blocking solution (3% normal goat serum, 3% bovine serum albumin, and 0.3% TritonX-100 in PBS) for 1 h. Primary antibodies against Fos (1:500, Cell Signaling Technology, #2250), GFP (1:1000, Thermo Fisher Scientific, #A11122), and mCherry (1:1000, Takara Bio Clontech, #632543) were diluted in blocking solution and sections were incubated overnight at 4°C with gentle shaking.

    Techniques: Activation Assay, Construct, Expressing, Over Expression, Injection, Two Tailed Test

    CaMKIIβ inhibition in the vCA1 increases stress susceptibility (A) AAV vectors used for the control construct (AAV-shControl) and CaMKIIβ knockdown (AAV-shCaMKIIβ). ITR, inverted terminal repeats; P CMV , cytomegalovirus promoter; P Camk2a , Camk2a promoter; U6, U6 promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental paradigm for behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (D) Specific knockdown of CaMKIIβ but not CaMKIIα by the AAV-shCaMKIIβ. (E–G) CaMKIIβ knockdown in the vCA1 of B6 mice leads to significantly decreased social interaction time in the SIT (E), decreased sucrose preference in SPT (F), and increased immobility time in FST (G) following CUMS exposure. n = 12–15 mice per group. (H) AAV vectors engineered to overexpress a constitutively active form of CaMKIIβ (CaMKIIβ-CA) with resistance against shCaMKIIβ (AAV-CaMKIIβ-CA Res ) or a control construct (AAV-mCherry). (I) Experimental paradigm for behavioral testing. (J) AAV microinjection into the vCA1. Region-specific expression of GFP and mCherry in the vCA1 is shown. Scale bar, 100 μm. (K and L) Overexpression of CaMKIIβ-CA Res together with shCaMKIIβ increases time in the interaction zone in the SIT (K) and tends to increase sucrose preference in the SPT (L) in B6 mice, when compared to the mice overexpressing mCherry together with shCaMKIIβ. n = 14–15 mice per group. (M) Experimental paradigm for behavioral testing. smSDS, subchronic and mild social defeat stress. (N) Decreased time in the interaction zone in B6 mice given AAV-shCaMKIIβ following smSDS exposure is prevented by overexpression of CaMKIIβ-CA Res . n = 15–16 mice per group. (O) AAV vectors engineered to overexpress a dominant-negative form of CaMKIIβ (AAV-CaMKIIβ-DN) or a control construct (AAV-GFP). (P) Experimental paradigm for behavioral testing. (Q) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (R–S) Overexpression of CaMKIIβ-DN decreases time in the interaction zone in the SIT (R) and sucrose preference in the SPT (S) in B6 mice following smSDS. n = 13–15 mice per group. (T) Overexpression of CaMKIIβ-DN decreases Fos levels in the vCA1 of B6 mice following smSDS exposure. n = 6 for all groups. Two-way ANOVA followed by a Tukey's post hoc test (in E-G, N, R, and S), one-way ANOVA followed by a Tukey's post hoc test (in N), and two-tailed Student's t-test (in K, L, and T) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also <xref ref-type=Figure S3 . Complete statistical summaries are provided in . " width="100%" height="100%">

    Journal: iScience

    Article Title: Gene-environment interactions mediate stress susceptibility and resilience through the CaMKIIβ/TARPγ-8/AMPAR pathway

    doi: 10.1016/j.isci.2021.102504

    Figure Lengend Snippet: CaMKIIβ inhibition in the vCA1 increases stress susceptibility (A) AAV vectors used for the control construct (AAV-shControl) and CaMKIIβ knockdown (AAV-shCaMKIIβ). ITR, inverted terminal repeats; P CMV , cytomegalovirus promoter; P Camk2a , Camk2a promoter; U6, U6 promoter; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (B) Experimental paradigm for behavioral testing. CUMS, chronic ultra-mild stress; SIT, social interaction test; SPT, sucrose preference test; FST, forced swim test. (C) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (D) Specific knockdown of CaMKIIβ but not CaMKIIα by the AAV-shCaMKIIβ. (E–G) CaMKIIβ knockdown in the vCA1 of B6 mice leads to significantly decreased social interaction time in the SIT (E), decreased sucrose preference in SPT (F), and increased immobility time in FST (G) following CUMS exposure. n = 12–15 mice per group. (H) AAV vectors engineered to overexpress a constitutively active form of CaMKIIβ (CaMKIIβ-CA) with resistance against shCaMKIIβ (AAV-CaMKIIβ-CA Res ) or a control construct (AAV-mCherry). (I) Experimental paradigm for behavioral testing. (J) AAV microinjection into the vCA1. Region-specific expression of GFP and mCherry in the vCA1 is shown. Scale bar, 100 μm. (K and L) Overexpression of CaMKIIβ-CA Res together with shCaMKIIβ increases time in the interaction zone in the SIT (K) and tends to increase sucrose preference in the SPT (L) in B6 mice, when compared to the mice overexpressing mCherry together with shCaMKIIβ. n = 14–15 mice per group. (M) Experimental paradigm for behavioral testing. smSDS, subchronic and mild social defeat stress. (N) Decreased time in the interaction zone in B6 mice given AAV-shCaMKIIβ following smSDS exposure is prevented by overexpression of CaMKIIβ-CA Res . n = 15–16 mice per group. (O) AAV vectors engineered to overexpress a dominant-negative form of CaMKIIβ (AAV-CaMKIIβ-DN) or a control construct (AAV-GFP). (P) Experimental paradigm for behavioral testing. (Q) AAV microinjection into the vCA1. Region-specific expression of GFP in vCA1 is shown. Scale bar, 100 μm. (R–S) Overexpression of CaMKIIβ-DN decreases time in the interaction zone in the SIT (R) and sucrose preference in the SPT (S) in B6 mice following smSDS. n = 13–15 mice per group. (T) Overexpression of CaMKIIβ-DN decreases Fos levels in the vCA1 of B6 mice following smSDS exposure. n = 6 for all groups. Two-way ANOVA followed by a Tukey's post hoc test (in E-G, N, R, and S), one-way ANOVA followed by a Tukey's post hoc test (in N), and two-tailed Student's t-test (in K, L, and T) were used for statistical analyses. ∗p < 0.05. Bar graphs show mean ± SEM. See also Figure S3 . Complete statistical summaries are provided in .

    Article Snippet: Free-floating sections were incubated with blocking solution (3% normal goat serum, 3% bovine serum albumin, and 0.3% TritonX-100 in PBS) for 1 h. Primary antibodies against Fos (1:500, Cell Signaling Technology, #2250), GFP (1:1000, Thermo Fisher Scientific, #A11122), and mCherry (1:1000, Takara Bio Clontech, #632543) were diluted in blocking solution and sections were incubated overnight at 4°C with gentle shaking.

    Techniques: Inhibition, Construct, Expressing, Over Expression, Dominant Negative Mutation, Two Tailed Test

    Journal: iScience

    Article Title: Gene-environment interactions mediate stress susceptibility and resilience through the CaMKIIβ/TARPγ-8/AMPAR pathway

    doi: 10.1016/j.isci.2021.102504

    Figure Lengend Snippet:

    Article Snippet: Free-floating sections were incubated with blocking solution (3% normal goat serum, 3% bovine serum albumin, and 0.3% TritonX-100 in PBS) for 1 h. Primary antibodies against Fos (1:500, Cell Signaling Technology, #2250), GFP (1:1000, Thermo Fisher Scientific, #A11122), and mCherry (1:1000, Takara Bio Clontech, #632543) were diluted in blocking solution and sections were incubated overnight at 4°C with gentle shaking.

    Techniques: Produced, Plasmid Preparation, Recombinant, SYBR Green Assay, Multiplex Assay, Mutagenesis, Staining, Western Blot, Real-time Polymerase Chain Reaction, Software